BioCentury | Feb 23, 2021
Distillery Therapeutics

Endocytic protein SH3GL1 as an autoimmune arthritis target

DISEASE CATEGORY: Autoimmune INDICATION: Arthritis; rheumatoid arthritis (RA) Inhibiting the endocytic protein SH3GL1 could treat autoimmune arthritis, including RA. CD4+ T cells from eight RA patients had higher mRNA levels of SH3GL1 than cells from...
BioCentury | Jan 23, 2021
Emerging Company Profile

ONK’s CAR NK cells hit the TRAIL

ONK thinks its engineered TRAIL variants will make CAR NK cells more potent and resistance-proof against both hematological and solid cancers.  The company, which spun out of National University of Ireland Galway in 2015, has applied...
BioCentury | Dec 7, 2018
Clinical News

Legend reports 15 months PFS for anti-BCMA CAR; questions over trial sites linger

Data presented on the most advanced Chinese CAR product at the American Society of Hematology (ASH) meeting don't shed much light on outstanding questions related to the company's data reports from the trial, but do...
BioCentury | Dec 4, 2018
Clinical News

Legend reports 15 months PFS for anti-BCMA CAR; questions over trial sites linger

Data presented on the most advanced Chinese CAR product at the American Society of Hematology (ASH) meeting on Monday don't shed much light on outstanding questions related to the company's data reports from the trial,...
BioCentury | Nov 26, 2018
Distillery Therapeutics

Neurology

...2018 doi:10.1111/jphp.13040 CONTACT: Ya-Jun Li, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China email: liyajun9@hotmail.com Claire Quang Xi'an Jiaotong University High...
BioCentury | Sep 28, 2018
Company News

Short seller accuses GenScript of CAR T data fraud

...of the hospitals participating in a Chinese trial of JNJ-68284528, the Second Affiliated Hospital of Xi'an Jiaotong University...
BioCentury | Sep 27, 2018
Company News

Short seller accuses GenScript of CAR T data fraud

...of the hospitals participating in a Chinese trial of LCAR-B38M, the Second Affiliated Hospital of Xi'an Jiaotong University...
BioCentury | Jun 13, 2018
Distillery Techniques

Disease models

...at Chapel Hill, Chapel Hill, N.C. email: zhi_liu@med.unc.edu Jaime De Leon University of North Carolina at Chapel Hill Xi'an Jiaotong University Collagen...
BioCentury | Dec 2, 2017
Strategy

Opening the gates in China

A flurry of approvals of HCV drugs in China this year illustrates how the country’s regulatory reforms have leveled the playing field for multinational drug sponsors, who had been disadvantaged compared with domestic companies. As...
BioCentury | Oct 17, 2017
Distillery Therapeutics

Hepatic

...Med .; published online Oct. 9, 2017 doi:10.1038/nm.4412 CONTACT: Yue Wu, First Affiliated Hospital of Xi'an Jiaotong University...
Items per page:
1 - 10 of 11
BioCentury | Feb 23, 2021
Distillery Therapeutics

Endocytic protein SH3GL1 as an autoimmune arthritis target

DISEASE CATEGORY: Autoimmune INDICATION: Arthritis; rheumatoid arthritis (RA) Inhibiting the endocytic protein SH3GL1 could treat autoimmune arthritis, including RA. CD4+ T cells from eight RA patients had higher mRNA levels of SH3GL1 than cells from...
BioCentury | Jan 23, 2021
Emerging Company Profile

ONK’s CAR NK cells hit the TRAIL

ONK thinks its engineered TRAIL variants will make CAR NK cells more potent and resistance-proof against both hematological and solid cancers.  The company, which spun out of National University of Ireland Galway in 2015, has applied...
BioCentury | Dec 7, 2018
Clinical News

Legend reports 15 months PFS for anti-BCMA CAR; questions over trial sites linger

Data presented on the most advanced Chinese CAR product at the American Society of Hematology (ASH) meeting don't shed much light on outstanding questions related to the company's data reports from the trial, but do...
BioCentury | Dec 4, 2018
Clinical News

Legend reports 15 months PFS for anti-BCMA CAR; questions over trial sites linger

Data presented on the most advanced Chinese CAR product at the American Society of Hematology (ASH) meeting on Monday don't shed much light on outstanding questions related to the company's data reports from the trial,...
BioCentury | Nov 26, 2018
Distillery Therapeutics

Neurology

...2018 doi:10.1111/jphp.13040 CONTACT: Ya-Jun Li, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China email: liyajun9@hotmail.com Claire Quang Xi'an Jiaotong University High...
BioCentury | Sep 28, 2018
Company News

Short seller accuses GenScript of CAR T data fraud

...of the hospitals participating in a Chinese trial of JNJ-68284528, the Second Affiliated Hospital of Xi'an Jiaotong University...
BioCentury | Sep 27, 2018
Company News

Short seller accuses GenScript of CAR T data fraud

...of the hospitals participating in a Chinese trial of LCAR-B38M, the Second Affiliated Hospital of Xi'an Jiaotong University...
BioCentury | Jun 13, 2018
Distillery Techniques

Disease models

...at Chapel Hill, Chapel Hill, N.C. email: zhi_liu@med.unc.edu Jaime De Leon University of North Carolina at Chapel Hill Xi'an Jiaotong University Collagen...
BioCentury | Dec 2, 2017
Strategy

Opening the gates in China

A flurry of approvals of HCV drugs in China this year illustrates how the country’s regulatory reforms have leveled the playing field for multinational drug sponsors, who had been disadvantaged compared with domestic companies. As...
BioCentury | Oct 17, 2017
Distillery Therapeutics

Hepatic

...Med .; published online Oct. 9, 2017 doi:10.1038/nm.4412 CONTACT: Yue Wu, First Affiliated Hospital of Xi'an Jiaotong University...
Items per page:
1 - 10 of 11